

Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Research Report 2023

<https://marketpublishers.com/r/G1AEDE936D22EN.html>

Date: December 2023

Pages: 90

Price: US\$ 2,900.00 (Single User License)

ID: G1AEDE936D22EN

Abstracts

AAV is transformed from a naturally occurring virus into a delivery mechanism for gene therapy. The viral DNA is replaced with new DNA, and it becomes a precisely coded vector and is no longer considered a virus, as most of the viral components have been replaced. The AAV Vector-Based Gene Therapy market size is anticipated to shoot up exponentially attributing to an increase in the approval of a growing number of gene therapies and readily adoption on approval, ability to treat a broad array of conditions, increasing prevalence of diseases, convenient one-time dosing approach and curative treatment options.

According to QYResearch's new survey, global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market is projected to reach US\$ 1106.4 million in 2029, increasing from US\$ 767 million in 2022, with the CAGR of 5.4% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market research.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high

costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market with multiple angles, which provides sufficient supports to readers' strategy and decision making.

By Company

BioMarin Pharmaceutical

Sangamo Therapeutics

Amicus Therapeutics

Roche

Pfizer

NightstaRx

MeiraGTx

Sarepta Therapeutics

Neurocrine Biosciences

Voyager Therapeutics

Asklepios Biopharmaceutical

Segment by Type

Single-stranded AAV (ssAAV)

Self-complementary AAV (scAAV)

Segment by Application

Hemophilia

Ophthalmology

Lysosomal Storage Disorders

Neurological Disorders

Others

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

The Adeno-Associated Virus (AAV) Vector-Based Gene Therapy report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)

Chapter 2: Global market size, regional market size. Market Opportunities and Challenges

Chapter 3: Companies' Competition Patterns

Chapter 4: Product Type Analysis

Chapter 5: Product Application Analysis

Chapter 6 to 10: Country Level Value Analysis

Chapter 11: Companies' Outline

Chapter 12: Market Conclusions

Chapter 13: Research Methodology and Data Source

Contents

1 REPORT OVERVIEW

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size
Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Single-stranded AAV (ssAAV)

1.2.3 Self-complementary AAV (scAAV)

1.3 Market by Application

1.3.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market
Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hemophilia

1.3.3 Ophthalmology

1.3.4 Lysosomal Storage Disorders

1.3.5 Neurological Disorders

1.3.6 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 GLOBAL GROWTH TRENDS

2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market
Perspective (2018-2029)

2.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Growth Trends by
Region

2.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size
by Region: 2018 VS 2022 VS 2029

2.2.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Size
by Region (2018-2023)

2.2.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market
Size by Region (2024-2029)

2.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Dynamics

2.3.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Trends

2.3.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers

2.3.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Challenges

2.3.4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players by Revenue

3.1.1 Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players by Revenue (2018-2023)

3.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Players (2018-2023)

3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue

3.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Concentration Ratio

3.4.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in 2022

3.5 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Key Players Head office and Area Served

3.6 Key Players Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Solution and Service

3.7 Date of Enter into Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market

3.8 Mergers & Acquisitions, Expansion Plans

4 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY BREAKDOWN DATA BY TYPE

4.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Size by Type (2018-2023)

4.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Type (2024-2029)

5 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY BREAKDOWN DATA BY APPLICATION

5.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market

Size by Application (2018-2023)

5.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)

6.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023)

6.4 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7 EUROPE

7.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)

7.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023)

7.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 ASIA-PACIFIC

8.1 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)

8.2 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market

Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2018-2023)

8.4 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 LATIN AMERICA

9.1 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)

9.2 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023)

9.4 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)

10.2 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023)

10.4 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 KEY PLAYERS PROFILES

11.1 BioMarin Pharmaceutical

11.1.1 BioMarin Pharmaceutical Company Detail

11.1.2 BioMarin Pharmaceutical Business Overview

11.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction

11.1.4 BioMarin Pharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)

11.1.5 BioMarin Pharmaceutical Recent Development

11.2 Sangamo Therapeutics

11.2.1 Sangamo Therapeutics Company Detail

11.2.2 Sangamo Therapeutics Business Overview

11.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction

11.2.4 Sangamo Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)

11.2.5 Sangamo Therapeutics Recent Development

11.3 Amicus Therapeutics

11.3.1 Amicus Therapeutics Company Detail

11.3.2 Amicus Therapeutics Business Overview

11.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction

11.3.4 Amicus Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)

11.3.5 Amicus Therapeutics Recent Development

11.4 Roche

11.4.1 Roche Company Detail

11.4.2 Roche Business Overview

11.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction

11.4.4 Roche Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)

11.4.5 Roche Recent Development

11.5 Pfizer

11.5.1 Pfizer Company Detail

11.5.2 Pfizer Business Overview

11.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction

11.5.4 Pfizer Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)

- 11.5.5 Pfizer Recent Development
- 11.6 NightstaRx
 - 11.6.1 NightstaRx Company Detail
 - 11.6.2 NightstaRx Business Overview
 - 11.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
 - 11.6.4 NightstaRx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
 - 11.6.5 NightstaRx Recent Development
- 11.7 MeiraGTx
 - 11.7.1 MeiraGTx Company Detail
 - 11.7.2 MeiraGTx Business Overview
 - 11.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
 - 11.7.4 MeiraGTx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
 - 11.7.5 MeiraGTx Recent Development
- 11.8 Sarepta Therapeutics
 - 11.8.1 Sarepta Therapeutics Company Detail
 - 11.8.2 Sarepta Therapeutics Business Overview
 - 11.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
 - 11.8.4 Sarepta Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
 - 11.8.5 Sarepta Therapeutics Recent Development
- 11.9 Neurocrine Biosciences
 - 11.9.1 Neurocrine Biosciences Company Detail
 - 11.9.2 Neurocrine Biosciences Business Overview
 - 11.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
 - 11.9.4 Neurocrine Biosciences Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
 - 11.9.5 Neurocrine Biosciences Recent Development
- 11.10 Voyager Therapeutics
 - 11.10.1 Voyager Therapeutics Company Detail
 - 11.10.2 Voyager Therapeutics Business Overview
 - 11.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
 - 11.10.4 Voyager Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-

Based Gene Therapy Business (2018-2023)

11.10.5 Voyager Therapeutics Recent Development

11.11 Asklepios Biopharmaceutical

11.11.1 Asklepios Biopharmaceutical Company Detail

11.11.2 Asklepios Biopharmaceutical Business Overview

11.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction

11.11.4 Asklepios Biopharmaceutical Revenue in Adeno-Associated Virus (AAV)

Vector-Based Gene Therapy Business (2018-2023)

11.11.5 Asklepios Biopharmaceutical Recent Development

12 ANALYST'S VIEWPOINTS/CONCLUSIONS

13 APPENDIX

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Type (US\$ Million): 2018 VS 2022 VS 2029

Table 2. Key Players of Single-stranded AAV (ssAAV)

Table 3. Key Players of Self-complementary AAV (scAAV)

Table 4. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth by Application (US\$ Million): 2018 VS 2022 VS 2029

Table 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2018-2023) & (US\$ Million)

Table 7. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region (2018-2023)

Table 8. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 9. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region (2024-2029)

Table 10. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Trends

Table 11. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers

Table 12. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Challenges

Table 13. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Restraints

Table 14. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Players (2018-2023) & (US\$ Million)

Table 15. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Players (2018-2023)

Table 16. Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy as of 2022)

Table 17. Ranking of Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies by Revenue (US\$ Million) in 2022

Table 18. Global 5 Largest Players Market Share by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (CR5 and HHI) & (2018-2023)

Table 19. Key Players Headquarters and Area Served

Table 20. Key Players Adeno-Associated Virus (AAV) Vector-Based Gene Therapy

Product Solution and Service

Table 21. Date of Enter into Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023) & (US\$ Million)

Table 24. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Type (2018-2023)

Table 25. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 26. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Type (2024-2029)

Table 27. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023) & (US\$ Million)

Table 28. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Application (2018-2023)

Table 29. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 30. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Application (2024-2029)

Table 31. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 32. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023) & (US\$ Million)

Table 33. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029) & (US\$ Million)

Table 34. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 35. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023) & (US\$ Million)

Table 36. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029) & (US\$ Million)

Table 37. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 38. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2018-2023) & (US\$ Million)

Table 39. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2024-2029) & (US\$ Million)

Table 40. Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy

Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 41. Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023) & (US\$ Million)

Table 42. Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029) & (US\$ Million)

Table 43. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 44. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023) & (US\$ Million)

Table 45. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029) & (US\$ Million)

Table 46. BioMarin Pharmaceutical Company Detail

Table 47. BioMarin Pharmaceutical Business Overview

Table 48. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product

Table 49. BioMarin Pharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US\$ Million)

Table 50. BioMarin Pharmaceutical Recent Development

Table 51. Sangamo Therapeutics Company Detail

Table 52. Sangamo Therapeutics Business Overview

Table 53. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product

Table 54. Sangamo Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US\$ Million)

Table 55. Sangamo Therapeutics Recent Development

Table 56. Amicus Therapeutics Company Detail

Table 57. Amicus Therapeutics Business Overview

Table 58. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product

Table 59. Amicus Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US\$ Million)

Table 60. Amicus Therapeutics Recent Development

Table 61. Roche Company Detail

Table 62. Roche Business Overview

Table 63. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product

Table 64. Roche Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US\$ Million)

Table 65. Roche Recent Development

Table 66. Pfizer Company Detail

Table 67. Pfizer Business Overview

Table 68. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product

Table 69. Pfizer Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US\$ Million)

Table 70. Pfizer Recent Development

Table 71. NightstaRx Company Detail

Table 72. NightstaRx Business Overview

Table 73. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product

Table 74. NightstaRx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US\$ Million)

Table 75. NightstaRx Recent Development

Table 76. MeiraGTx Company Detail

Table 77. MeiraGTx Business Overview

Table 78. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product

Table 79. MeiraGTx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US\$ Million)

Table 80. MeiraGTx Recent Development

Table 81. Sarepta Therapeutics Company Detail

Table 82. Sarepta Therapeutics Business Overview

Table 83. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product

Table 84. Sarepta Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US\$ Million)

Table 85. Sarepta Therapeutics Recent Development

Table 86. Neurocrine Biosciences Company Detail

Table 87. Neurocrine Biosciences Business Overview

Table 88. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product

Table 89. Neurocrine Biosciences Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US\$ Million)

Table 90. Neurocrine Biosciences Recent Development

Table 91. Voyager Therapeutics Company Detail

Table 92. Voyager Therapeutics Business Overview

Table 93. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product

Table 94. Voyager Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US\$ Million)

Table 95. Voyager Therapeutics Recent Development

Table 96. Asklepios Biopharmaceutical Company Detail

Table 97. Asklepios Biopharmaceutical Business Overview

Table 98. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product

Table 99. Asklepios Biopharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US\$ Million)

Table 100. Asklepios Biopharmaceutical Recent Development

Table 101. Research Programs/Design for This Report

Table 102. Key Data Information from Secondary Sources

Table 103. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Comparison by Type (2023-2029) & (US\$ Million)

Figure 2. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type: 2022 VS 2029

Figure 3. Single-stranded AAV (ssAAV) Features

Figure 4. Self-complementary AAV (scAAV) Features

Figure 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Comparison by Application (2023-2029) & (US\$ Million)

Figure 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application: 2022 VS 2029

Figure 7. Hemophilia Case Studies

Figure 8. Ophthalmology Case Studies

Figure 9. Lysosomal Storage Disorders Case Studies

Figure 10. Neurological Disorders Case Studies

Figure 11. Others Case Studies

Figure 12. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Report Years Considered

Figure 13. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (US\$ Million), Year-over-Year: 2018-2029

Figure 14. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, (US\$ Million), 2018 VS 2022 VS 2029

Figure 15. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region: 2022 VS 2029

Figure 16. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Players in 2022

Figure 17. Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy as of 2022)

Figure 18. The Top 10 and 5 Players Market Share by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in 2022

Figure 19. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 20. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Country (2018-2029)

Figure 21. United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy

Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 22. Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 23. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 24. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Country (2018-2029)

Figure 25. Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 26. France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 27. U.K. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 28. Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 29. Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 30. Nordic Countries Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 31. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 32. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region (2018-2029)

Figure 33. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 34. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 35. South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 36. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 37. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 38. Australia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 39. Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 40. Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Country (2018-2029)

Figure 41. Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 42. Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 43. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 44. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Country (2018-2029)

Figure 45. Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 46. Saudi Arabia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 47. BioMarin Pharmaceutical Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)

Figure 48. Sangamo Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)

Figure 49. Amicus Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)

Figure 50. Roche Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)

Figure 51. Pfizer Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)

Figure 52. NightstaRx Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)

Figure 53. MeiraGTx Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)

Figure 54. Sarepta Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)

Figure 55. Neurocrine Biosciences Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)

Figure 56. Voyager Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)

Figure 57. Asklepios Biopharmaceutical Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)

Figure 58. Bottom-up and Top-down Approaches for This Report

Figure 59. Data Triangulation

Figure 60. Key Executives Interviewed

I would like to order

Product name: Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Research Report 2023

Product link: <https://marketpublishers.com/r/G1AEDE936D22EN.html>

Price: US\$ 2,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1AEDE936D22EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

